Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Newly discovered protein may be key to muscular dystrophy

19.08.2004


A defect in the action of a newly discovered protein may play a central role in muscular dystrophy, a disease of progressive muscle degeneration with no known cure.



Scientists at UCSF’s Ernest Gallo Clinic and Research Center discovered in an animal model of the disease that during periods of intense muscle activity, muscles remain excited too long and degenerate if the protein fails to transport the neurotransmitter acetylcholine away from the nerve-muscle synapse. Muscle degeneration is the hallmark of muscular dystrophy, one of the most common genetic diseases.

The study was carried out in the roundworm, C. elegans, an animal which has provided early clues to the role of a number of important molecules in the human nervous system. The researchers expect that the protein, which they showed is an acetylcholine transporter, plays the same role in humans as it does in C. elegans, identifying a potential new route for treatment of muscular dystrophy.


The research is being reported in the August 19 issue of the journal Nature.

Normally, a nerve cell induces a muscle cell to contract by releasing the neurotransmitter acetylcholine at the synapse -- the junction where the two cells meet. Researchers have identified transporters for most neurotransmitters, such as serotonin, dopamine and glutamate. The transporters remove neurotransmitters from the synapse, in effect providing an "off" switch to the neurotransmitter’s potent effects. It was thought that normal enzymatic breakdown of acetylcholine was so effective that a transporter wasn’t needed to clear excess acetylcholine from the synapse. But the scientists found that during periods of intense muscle activity, a transporter must clear acetylcholine from the synapse.

"Discovering a transporter for acetylcholine was quite a surprise," said Steven McIntire, MD, PhD, UCSF assistant professor of neurology. "Identification of an acetylcholine transporter in mammals could lead to useful therapeutics to treat neuromuscular diseases as well as disorders of the central nervous system." McIntire is a principal investigator at the UCSF-affiliated Gallo Clinic and Research Center, and is senior author on the Nature paper.

Transporters have proven to be important drug targets, McIntire said. Prozac, for example, modulates a transporter that regulates serotonin concentration. Besides carrying messages from nerve cells to muscle cells, acetylcholine triggers communication between neurons in the brain, and is involved directly or indirectly in many diseases, including Alzheimer’s and diseases of peripheral nerves. Discovery of the acetylcholine transporter could lead to therapies for some of these diseases based on altering acetylcholine levels, he said.

Duchenne muscular dystrophy, the most common form of the disease, primarily affects boys -- about one in 3,500 male births. It typically begins in early childhood. Children often experience leg weakness, falling and progressive loss of movement, eventually becoming wheel chair-dependent. Many die in their late teens or early twenties. Currently, there is no cure.

Scientists already knew that muscular dystrophy results from genetic defects in components of a network of proteins, known as the dystrophin-glycoprotein complex (DGC),that extends through the entire muscle cell membrane, linking the framework inside the cell to the region outside of the cell. The complex is found in C. elegans, in mice and in humans. In each species, defects in the complex can cause muscle degeneration, but the exact role of the complex in disease has not been clear.

In a genetic screen, the scientists identified 12 mutations which produced defects in coordinated movement just like those found in C. elegans DGC mutants -- a model for human muscular dystrophy. While seven of the mutants involved defective DGC function, five others resulted from variations in a previously unidentified gene. The team cloned this gene, snf-6, and found that its sequence was similar to genes in a family of mammalian neurotransmitter transporters. Because analysis of mutants indicated defects in acetylcholine activity, they tested whether the expressed protein, SNF-6, transports acetylcholine in mammalian cells grown in culture. They found that it is indeed an acetylcholine transporter.

The team used fluorescence techniques to determine that the distribution of SNF-6 was altered in DGC mutants. They found that the DGC, imbedded in the muscle cell membrane, maintains the neurotransmitter transporter at the neuromuscular synapse. In this location, the transporter is available to clear excess acetylcholine.

Further studies confirmed that when acetylcholine transporter function is disrupted, whether by defects in the DGC protein complex that maintains the transporter, or by genetic defects in the transporter itself, the result is muscle degeneration typical of muscular dystrophy.

"We hope that these findings will ultimately lead to an effective treatment for common forms of muscular dystrophy," McIntire said.

Wallace Ravven | EurekAlert!
Further information:
http://www.ucsf.edu

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>